Zhejiang Hisun – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:19:04 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Zhejiang Hisun – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Tigecycline Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-tigecycline-market-2021-2025/ Mon, 19 Jul 2021 02:43:42 +0000 https://www.cri-report.com/?post_type=product&p=13255 Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of tigecycline in the Chinese market decreased to CNY 885 million in 2020 and the CAGR of tigecycline sales value from 2016 to 2020 is 28.64%.

The post Investigation Report on China’s Tigecycline Market 2021-2025 first appeared on CRI Report.

]]> Tigecycline is a broad-spectrum glycyl cyclic peptide antibiotic administered intravenously. Tigecycline is approved for complicated skin and skin structure infections or complicated intra-abdominal infections patients aged 18 and over. These infections include complicated appendicitis, burn infection, intra-abdominal abscess, deep soft tissue infection and ulcer infection. Tigecycline was developed by Wyeth Corporation of the United States and was listed in China under the trade name TYGACIL in 2011. Subsequently, some generic drugs from local Chinese companies were listed. By 2020, tigecycline has been included in China’s Class B medical insurance, and there are several manufacturers in the Chinese tigecycline market.

According to CRI’s market research, the sales value of tigecycline in the Chinese market increased year by year at a compound annual growth rate of 43.45% from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of tigecycline in the Chinese market decreased to CNY 885 million in 2020 and the CAGR of tigecycline sales value from 2016 to 2020 is 28.64%.

CRI expects that the sales value of tigecycline in the Chinese market will have a restorative growth from 2016 to 2020 with the relief of COVID-19. According to the latest set of data disclosed by the World Health Organization, 700,000 people worldwide die each year due to “super bacteria” infection, and 230,000 newborns die prematurely because of this. It can be estimated that by 2050, the number of deaths may exceed 10 million. Therefore, the sales value and sales volume of tigecycline against “super bacteria” such as methicillin-resistant Staphylococcus aureus (MRSA) will continue to rise. By the first half of 2021, the new indication for tigecycline in the Chinese market-community and hospital-acquired pneumonia is under review. It can be expected that with the increase in new indications in the future, the sales value and sales volume of tigecycline have room to rise.

 

Topics Covered:

  • -The impact of COVID-19 on China’s Tigecycline market
  • – Sales value of China’s Tigecycline 2016-2020
  • – Competitive landscape of China’s Tigecycline market
  • – Prices of Tigecycline in China
  • – Prices of Tigecycline in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Tigecycline market
  • – Prospect of China’s Tigecycline market from 2021 to 2025

The post Investigation Report on China’s Tigecycline Market 2021-2025 first appeared on CRI Report.

]]>